{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:52:10Z","timestamp":1758970330036},"reference-count":21,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.clinthera.2017.08.022","type":"journal-article","created":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T04:00:16Z","timestamp":1507176016000},"page":"2260-2275.e1","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects"],"prefix":"10.1016","volume":"39","author":[{"given":"Helen","family":"Tomkinson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen","family":"McBride","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleanor","family":"Lisbon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela W.","family":"Dymond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireille","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"So","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Holt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2017.08.022_bib1","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/1078-0432.CCR-06-1150","article-title":"Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1\/2 inhibitor","volume":"13","author":"Yeh","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2017.08.022_bib2","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1158\/1078-0432.CCR-09-2483","article-title":"The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1\/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer","volume":"16","author":"Banerji","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2017.08.022_bib3","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00280-010-1323-z","article-title":"Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice","volume":"67","author":"Denton","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clinthera.2017.08.022_bib4","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2017.08.022_bib5","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.molonc.2007.12.003","article-title":"Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site","volume":"1","author":"Platz","year":"2008","journal-title":"Mol Oncol"},{"key":"10.1016\/j.clinthera.2017.08.022_bib6","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1056\/NEJMoa1209288","article-title":"Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer","volume":"368","author":"Ho","year":"2013","journal-title":"N Engl J Med"},{"issue":"Suppl 5","key":"10.1016\/j.clinthera.2017.08.022_bib7","article-title":"Phase I study of the MEK1\/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs)","volume":"32","author":"Widemann","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2017.08.022_bib8","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1016\/j.clinthera.2016.09.002","article-title":"The metabolism, excretion, and pharmacokinetics of selumetinib, a MEK1\/2 inhibitor, in healthy adult male subjects","volume":"38","author":"Dymond","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2017.08.022_bib9","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1200\/JCO.2007.14.4956","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1\/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers","volume":"26","author":"Adjei","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2017.08.022_bib10","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1001\/jama.2014.6096","article-title":"Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial","volume":"311","author":"Carvajal","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2017.08.022_bib11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1470-2045(12)70489-8","article-title":"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study","volume":"14","author":"J\u00e4nne","year":"2013","journal-title":"Lancet Onol"},{"key":"10.1016\/j.clinthera.2017.08.022_bib12","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1470-2045(13)70237-7","article-title":"Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study","volume":"14","author":"Robert","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2017.08.022_bib13","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.4155\/bio-2016-0082","article-title":"Determination of selumetinib, N-desmethyl selumetinib and selumetinib amide in human biological samples by LC-MS\/MS","volume":"8","author":"Severin","year":"2016","journal-title":"Bioanalysis"},{"key":"10.1016\/j.clinthera.2017.08.022_bib14","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cllc.2015.12.010","volume":"17","author":"J\u00e4nne","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.clinthera.2017.08.022_bib15","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1007\/s00280-011-1732-7","article-title":"A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1\/2 inhibitor selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors","volume":"68","author":"Leijen","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clinthera.2017.08.022_bib16","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrc1629","article-title":"Pharmacokinetic variability of anticancer agents","volume":"5","author":"Undevia","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clinthera.2017.08.022_bib17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pharmthera.2015.05.009","article-title":"Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors","volume":"152","author":"Terada","year":"2015","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2017.08.022_bib18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00228-016-2153-7","article-title":"Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK 1\/2 inhibitor, in healthy volunteers: results from two clinical trials","volume":"73","author":"Dymond","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2017.08.022_bib19","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0278-6915(02)00209-0","article-title":"Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment","volume":"41","author":"Dorne","year":"2003","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.clinthera.2017.08.022_bib20","first-page":"1318","article-title":"Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion","volume":"49","author":"Choi","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinthera.2017.08.022_bib21","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S0959-8049(98)00230-5","article-title":"Pharmacogenetics and cancer chemotherapy","volume":"34","author":"Iyer","year":"1998","journal-title":"Eur J Cancer"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817309438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817309438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T17:03:12Z","timestamp":1530205392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291817309438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0149291817309438"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.08.022","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.08.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}